Compare TSQ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSQ | AGEN |
|---|---|---|
| Founded | 1996 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 126.2M |
| IPO Year | 2000 | 2000 |
| Metric | TSQ | AGEN |
|---|---|---|
| Price | $5.06 | $3.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $12.50 | ★ $14.50 |
| AVG Volume (30 Days) | 72.0K | ★ 604.5K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | ★ 15.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $438,695,000.00 | $106,829,000.00 |
| Revenue This Year | N/A | $67.15 |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | $4.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.30 | $1.38 |
| 52 Week High | $10.23 | $7.34 |
| Indicator | TSQ | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 31.67 |
| Support Level | $5.13 | $3.26 |
| Resistance Level | $5.34 | $4.00 |
| Average True Range (ATR) | 0.25 | 0.25 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 44.16 | 30.49 |
Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the premier local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and premier national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).